Davis Polk and Latham lead on Roche megadeal

A duo of US firms have snared lead roles on Swiss pharmaceutical group Roche's $43.7bn bid for US drug giant Genentech. Davis Polk & Wardwell New York partners Arthur Golden, Chris Mayer and Peter Douglas are advising Roche. It is thought Latham & Watkins' global head of corporate Peter Kerman will lead the firm on advice to existing Latham client Genentech.